Clinical Trials Logo

Clinical Trial Summary

This trial attempts to evaluate the treatment efficacy of magnetic seizure therapy (MST) and its safety for bipolar mania. Half of the participants will receive MST, while the other half will receive electroconvulsive therapy (ECT).


Clinical Trial Description

Magnetic seizure therapy (MST) is likely to be an alternative options to electroconvulsive therapy (ECT). Widespread stimulation of cortical and subcortical regions is inevitable for ECT since the substantial impedance of the scalp and skull shuts most of the electrical stimulus away from the brain. Nevertheless, magnetic pulses are capable to focus the stimulus to a specific area of the brain because they can pass the scalp and skull without resistance. In Addition, electric current will penetrate into deeper structures, while magnetic stimulus are only capable to reach a depth of a few centimeters. As a consequence, MST are able to generate focus stimuli on superficial regions of the cortex while ECT can't, which may give MST the capability to produce comparable therapeutic benefits with the absence of apparent cognitive side effects. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03160664
Study type Interventional
Source Shanghai Mental Health Center
Contact
Status Completed
Phase N/A
Start date July 1, 2017
Completion date April 26, 2021

See also
  Status Clinical Trial Phase
Completed NCT03857438 - Correlation of Audiovisual Features With Clinical Variables and Neurocognitive Functions in Bipolar Disorder, Mania
Completed NCT03013400 - Ebselen as an add-on Treatment in Hypo/Mania Phase 2
Completed NCT04420793 - Voice Changes During ECT
Withdrawn NCT03016104 - Magnetic Seizure Therapy vs. Electroconvulsive Therapy for Bipolar Mania N/A
Terminated NCT00329108 - Ziprasidone And Olanzapine's Outcomes In Mania Phase 4
Terminated NCT04058249 - Accelerated Theta Burst Stimulation for Inpatients With Bipolar Disorder N/A
Recruiting NCT06462586 - Study of Lumateperone in the Acute Treatment of Patients With Bipolar Mania Phase 3
Not yet recruiting NCT06462612 - Study of Lumateperone in the Treatment of Patients With Bipolar Mania Phase 3